EDINBURGH MOLECULAR IMAGING
See. Treat. Cure.
Highly Specific Cancer Targeting
Using its proprietary platform technology, EM Imaging is developing a pipeline of highly novel in vivo c-Met targeting theragnostic and optical imaging agents that will alter the landscape of precision medicine.
EM Imaging has a portfolio of agents addressing a number of unmet medical needs
Ongoing Clinical Studies
EM Imaging is focused on the development of fluorescent optical imaging and therapeutic agents. Our current clinical trials are detailled in a dedicated section.
Latest Press Release
Edinburgh Molecular Imaging Closes Financing
To accelerate evelopment of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – 17 December 2019 – Edinburgh Molecular Imaging Ltd,...
Our Latest News
Results published by Investigator on non-invasive assessment of c-MET expression in non-small cell lung cancer
A case of a 56-year-old female former smoker with stage IV EGFR mutation-positive NSCLC (lymphogenic, pulmonary, hepatic, and cerebral metastases is presented. Stage: cT3, cN3, cM1b) and concomitant...
Results published by Investigator on identification and validation of MET as target for fluorescent guided surgery in papillary thyroid cancer
Patients undergoing prophylactic central compartment dissection (PCLND) for papillary thyroid cancer (PTC) are often overtreated. This study aimed to determine if molecular fluorescence-guided...